 |
|
New blood clot guidelines for pregnant women
June 25, 2008Blood clot recommendations highlight challenges for pediatric and pre-surgery populations
New evidence-based guidelines address the prevention and management of thrombosis in key patient populations and reinforce recommendations related to the routine use of preventive therapies. Published as a supplement in the June issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), Antithrombotic and Thrombolytic Therapy: ACCP Evidence-Based Clinical Practice Guidelines, Eighth Edition was developed by an international panel of 90 experts and includes more than 700 of the most comprehensive recommendations related to the prevention, treatment, and long-term management of thrombotic disorders. The guidelines include chapters on the challenges in preventing and treating thrombosis in pregnant women and children, and on managing peri- and postoperative patients, while also reinforcing previous guidelines related to the routine use of preventive therapies, including aspirin.
"For years, clinicians have faced challenges in preventing and managing thrombosis in women who are pregnant or patients who require surgery," said guidelines panel chair Jack Hirsh, MD, FCCP, Henderson Research Center, Hamilton, ON, Canada. "The new guidelines address many troublesome issues in antithrombotic therapy and provide clinicians with a variety of options for care in special patient groups." Antithrombotic and thrombolytic therapies are used to prevent and treat thrombosis or blood clotting that arises in arteries, veins, and the heart.
PREGNANT WOMEN
The new ACCP guidelines address challenging issues facing women who are pregnant or wish to become pregnant while undergoing long-term antithrombotic therapy. Pregnant women taking vitamin K antagonists (VKA), such as the anticoagulant warfarin, have an increased risk for birth defects and miscarriage and are, therefore, advised to stop taking VKAs before 6 weeks of fetal gestation. However, some pregnant women with certain types of mechanical heart valves may be continued on VKA therapy because of concerns about the effectiveness of alternative anticoagulants in preventing stroke and valve thrombosis. For other women taking VKAs who become pregnant, the guidelines recommend substituting low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH). The guidelines recommend two options for doing this: (1) continuing VKA but performing frequent pregnancy tests to determine when pregnancy has been achieved, followed by the substituion of LMWH or UFH as therapy; or (2) substituting VKAs with LMWH or UFH prior to conception. Although the second option eliminates the potential for fetal exposure to VKA, it provides additional challenges. LMWH and UFH are more expensive than VKAs and must be administered through a once- or twice-daily injection as opposed to a once daily oral dose of VKAs. In addition, long-term use of LMWH or UFH can be associated with osteoporosis.
"If women substitute heparin prior to pregnancy and have difficulties conceiving, they may find themselves taking the medication for a much longer timeframe than expected," said guideline coauthor Shannon Bates, MD, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada. "This is not only inconvenient but also increases treatment costs and may be associated with long-term risks for the mother."
CHILDREN
Recommendations related to childhood stroke, one of the top ten causes of death in children, and congenital heart disease have been substantially expanded since the previous guideline. Arterial ischemic stroke (AIS), usually caused by embolism or thrombosis, is difficult to diagnose in children because underlying health conditions are markedly different than those in adult stroke and up to 15% of children with AIS have no apparent risk factors. The guidelines recommend that children with AIS receive initial antithrombotic therapy until underlying causes can be determined, followed by maintenance therapy to prevent long-term recurrence. In addition, the newly expanded guidelines on the prevention and treatment of thrombosis related to congenital heart disease interventions include discussions of ventricular assist devices and prosthetic heart valves.
"Care for children with major cardiac problems has improved dramatically. Many children who previously died now survive, but thrombosis remains a major cause of secondary complications for these children," said Dr. Hirsh. "Effective antithrombotic therapy is critical if these children are to grow up as normal, healthy children."
PATIENTS UNDERGOING SURGERY
For the first time, the guidelines dedicate a full chapter to the perioperative management of patients on long-term antithrombotic therapy who require surgery or other invasive procedures. Most patients must temporarily stop receiving therapy just prior to undergoing surgery, as well as during surgery, in order to minimize surgery-related bleeding. However, stopping antithrombotic therapy can increase the risk of a thromboembolic event. To address this challenge, the guidelines recommend that the risk of a thromboembolic event during interruption of therapy is balanced against the risk for bleeding when antithrombotic therapy is discontinued just prior to surgery. The guidelines also recommend routine use of thromboprophylaxis for patients undergoing major general, gynecologic, or orthopedic surgeries and have been expanded to include bariatric and coronary artery bypass surgery.
GENERAL RECOMMENDATIONS
Overall, ACCP guidelines recommend thromboprophylaxis for most patients who are hospitalized; however, they do not recommend routine use of thromboprophylaxis for patient groups with a very low risk of venous thromboembolism. Low risk groups include patients undergoing laparoscopic surgery, knee arthroscopy, or those who take long airplane flights. For these patients, physicians can make decisions about thromboprophylaxis based on the individual patient's thrombosis risk. The guidelines continue to recommend against the use of aspirin alone as a means to prevent venous thromboembolism in any patient population because more effective methods are available.
American College of Chest Physicians
PREGNANT WOMEN
The new ACCP guidelines address challenging issues facing women who are pregnant or wish to become pregnant while undergoing long-term antithrombotic therapy. Pregnant women taking vitamin K antagonists (VKA), such as the anticoagulant warfarin, have an increased risk for birth defects and miscarriage and are, therefore, advised to stop taking VKAs before 6 weeks of fetal gestation. However, some pregnant women with certain types of mechanical heart valves may be continued on VKA therapy because of concerns about the effectiveness of alternative anticoagulants in preventing stroke and valve thrombosis. For other women taking VKAs who become pregnant, the guidelines recommend substituting low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH). The guidelines recommend two options for doing this: (1) continuing VKA but performing frequent pregnancy tests to determine when pregnancy has been achieved, followed by the substituion of LMWH or UFH as therapy; or (2) substituting VKAs with LMWH or UFH prior to conception. Although the second option eliminates the potential for fetal exposure to VKA, it provides additional challenges. LMWH and UFH are more expensive than VKAs and must be administered through a once- or twice-daily injection as opposed to a once daily oral dose of VKAs. In addition, long-term use of LMWH or UFH can be associated with osteoporosis.
"If women substitute heparin prior to pregnancy and have difficulties conceiving, they may find themselves taking the medication for a much longer timeframe than expected," said guideline coauthor Shannon Bates, MD, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada. "This is not only inconvenient but also increases treatment costs and may be associated with long-term risks for the mother."
CHILDREN
Recommendations related to childhood stroke, one of the top ten causes of death in children, and congenital heart disease have been substantially expanded since the previous guideline. Arterial ischemic stroke (AIS), usually caused by embolism or thrombosis, is difficult to diagnose in children because underlying health conditions are markedly different than those in adult stroke and up to 15% of children with AIS have no apparent risk factors. The guidelines recommend that children with AIS receive initial antithrombotic therapy until underlying causes can be determined, followed by maintenance therapy to prevent long-term recurrence. In addition, the newly expanded guidelines on the prevention and treatment of thrombosis related to congenital heart disease interventions include discussions of ventricular assist devices and prosthetic heart valves.
"Care for children with major cardiac problems has improved dramatically. Many children who previously died now survive, but thrombosis remains a major cause of secondary complications for these children," said Dr. Hirsh. "Effective antithrombotic therapy is critical if these children are to grow up as normal, healthy children."
PATIENTS UNDERGOING SURGERY
For the first time, the guidelines dedicate a full chapter to the perioperative management of patients on long-term antithrombotic therapy who require surgery or other invasive procedures. Most patients must temporarily stop receiving therapy just prior to undergoing surgery, as well as during surgery, in order to minimize surgery-related bleeding. However, stopping antithrombotic therapy can increase the risk of a thromboembolic event. To address this challenge, the guidelines recommend that the risk of a thromboembolic event during interruption of therapy is balanced against the risk for bleeding when antithrombotic therapy is discontinued just prior to surgery. The guidelines also recommend routine use of thromboprophylaxis for patients undergoing major general, gynecologic, or orthopedic surgeries and have been expanded to include bariatric and coronary artery bypass surgery.
GENERAL RECOMMENDATIONS
Overall, ACCP guidelines recommend thromboprophylaxis for most patients who are hospitalized; however, they do not recommend routine use of thromboprophylaxis for patient groups with a very low risk of venous thromboembolism. Low risk groups include patients undergoing laparoscopic surgery, knee arthroscopy, or those who take long airplane flights. For these patients, physicians can make decisions about thromboprophylaxis based on the individual patient's thrombosis risk. The guidelines continue to recommend against the use of aspirin alone as a means to prevent venous thromboembolism in any patient population because more effective methods are available.
American College of Chest Physicians
Thrombosis Current Events and Thrombosis News RSSPneumatosis cystoids intestinalis after fluorouracil chemotherapy
The mechanism of pneumatosis cystoids intestinalis (PCI) is unclear. The mechanical and bacterial factors are most predominant causes of PCI.
ESF study helps stop drugs slipping through safety net
Recent advances in genetic screening will lead to safer pharmaceutical drugs, with reduced adverse side effects, if the methods are incorporated in clinical development.
Mayo Clinic Chest Surgeons Propose Measures for Indicating Quality of Lung Surgery
Even though 30,000 patients in the United States undergo lung surgery each year, no standard criteria exist to measure the quality of their care. In the current issue of The Annals of Thoracic Surgery, Mayo Clinic surgeons have proposed a system of lung surgery quality indicators for surgeons and the public as a method to demonstrate best practices for obtaining positive patient outcomes.
DES: New elements in the debate
Results announced at the 2006 ESC meeting in Barcelona questioned the long-term safety of drug eluting stents (DES) and sparked intense discussion.
Best use of drug-eluting stents
Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction.
Tiny 3-D ultrasound probe guides catheter procedures
An ultrasound probe small enough to ride along at the tip of a catheter can provide physicians with clearer real-time images of soft tissue without the risks associated with conventional x-ray catheter guidance.
AJN study reveals compression stockings incorrectly used in 29 percent of patients
An original study, published in the September issue of the American Journal of Nursing (AJN), revealed that graduated compression stockings were used incorrectly in 29% of the patients and sized incorrectly in 26% of the patients.
Computers as safe as medical experts for prescribing blood thinning drugs
The largest ever study into the administration of blood thinning drugs, principally Warfarin, has concluded that dosages calculated by computer are at least as safe and reliable as those provided by expert medical professionals.
Study shows pine bark naturally reduces cardiovascular risk factors in diabetics
A new study published in the May 2008 (volume 8, issue 25) edition of the journal of Nutrition Research shows Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, reduces blood sugar in type II diabetes patients, allows people to lower their antihypertensive medication and improves cardiovascular disease (CVD) risk factors.
Quest for better treatment for effects of menopause
During menopause, lack of oestrogens increases the risk of suffering cardiovascular diseases. For her doctoral thesis, University of the Basque Country researcher, Ainhoa Ruiz del Agua, studied the effects of substitute treatments and the genetic factors influencing the response to these therapies.
More Thrombosis Current Events and Thrombosis News Articles
 | Hemostasis and Thrombosis: Basic Principles and Clinical Practice (HEMOSTASIS AND THROMBOSIS) The pre-eminent reference on coagulation disorders is now in its thoroughly updated Fifth Edition. Written by more than 160 of the world's foremost authorities, this encyclopedic volume integrates basic science and clinical practice and details all that is currently known about blood clotting disorders and how to manage patients with these and related problems. This edition has been reorganized... |
 | Disorders of Hemostasis & Thrombosis: A Clinical Guide by Scott H. Goodnight, William E. Hathaway Now expanded with new coverage of genetics, more therapy and management strategies, and more references throughout, this guide remains one of the most practical resources for diagnosis and treatment of hematologic conditions commonly seen in general practice. The clear, succinct language is meant for the non-hematologist who wants the salient points of clinical signs, etiology and... |
| Quality in Laboratory Hemostasis and Thrombosis by Eric Preston, Steve Kitchen, John Olson | |
 | Consultative Hemostasis and Thrombosis by Craig S. Kitchens, Barbara M. Alving, Craig M. Kessler Effectively and efficiently diagnose and manage today's full range of clotting and bleeding disorders using clinical case studies that demonstrate real-world problems and solutions! For each condition examined, you'll review concise descriptions of its associated symptoms, along with laboratory findings, diagnosis, differential diagnosis, and treatment - all the clinical guidance you need - at... |
| Disorders of Thrombosis and Hemostasis: Clinical and Laboratory Practice, 3rd ed. , hc, 2002 by Rodger L. Bick | |
 | Thrombosis: Everything You Need to Know (Your Personal Health) by Jack Hirsh A layperson's guide to a debilitating condition. Thrombosis is the formation of a solid blood clot in an arterial or venous vessel where it can interfere with normal blood flow. About 1 in 20 suffers from vein clots or lung clots at some point, and about half of those suffering from thrombosis have other illnesses such as cancer or develop the clot while recovering from surgery or a... |
 | 100 Q&A About Deep Vein Thrombosis and Pulmonary Embolism (100 Questions & Answers about . . .) (100 Questions & Answers) by Andra H. James Nearly two million Americans are affected annually by deep vein thrombosis. Whether you're a newly diagnosed patient, or a loved one of someone suffering from this disease, this book offers help. The only text available to provide both the doctor's and patient's views, 100 Questions & Answers About Deep Vein Thrombosis and Pulmonary Embolism gives you authoritative, practical answers to your... |
 | Recent Advances in Thrombosis and Hemostasis by Y. Ikeda Thrombotic and thromboembolic disorders, in particular, thrombosis complicating life style-related diseases such as malignancies and arterioscleosis resulting from diabetes mellitus, hypertension, obesity and others, are now, more than ever, the leading causes of morbidity and mortality and become the common medico-social problem with economic consequences in the industrialized and developing... |
 | Handbook on Cerebral Venous Thrombosis (Frontiers of Neurology and Neuroscience) Cerebral veins contain about 70% of the total cerebral blood volume, but cerebral venous thrombosis (CVT) occurs about a thousand times less often than arterial stroke. CVT affects mostly young adults and children, and in about one quarter of cases the cause remains unknown. Written by international experts, this publication is dealing with epidemiology, risk factors, coagulation... |
| Disorders of Thrombosis Foothills Hospital, Calgary. Text correlating current laboratory and clinical knowledge of thrombotic disorders to assist in the prevention and treatment of systemic and venous thromboembolism. For cardiologists, internists, and primary care physicians. 63 contributors, 28 U.S. DNLM:... |
| © 2008 BrightSurf.com |